Percentages of patients with GBS, CIDP, or ON and healthy controls (HC) responding with positive antigen specific ELISPOT IFN-γ and IL-5 reactivity to specific peptides and whole MBP
| Antigen specific cytokine secretion | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMP22 | P0 | P2 | MBP | |||||||||||||||||||||
| 32–51 | 41–61 | 51–64 | 120–133 | 56–71 | 70–85 | 180–199 | 14–25 | 61–70 | 82–100 | Whole | All antigens | |||||||||||||
| Results from cells/106 PBMC. The healthy control mean+2SD of antigen specific PBMC for each of the test antigens was used as a threshold to classify responses into positive or negative for each subject. Threshold values are expressed as antigen specific cells/106 PBMC. | ||||||||||||||||||||||||
| IFN-γ | ||||||||||||||||||||||||
| Threshold | 7.7 | 10.9 | 13.8 | 12.9 | 26.4 | 11.6 | 8.5 | 8.1 | 18.9 | 16.4 | 20.3 | |||||||||||||
| GBS | 18.7 | 12.5 | 12.5 | 6.2 | 12.5 | 25.0 | 12.5 | 0 | 18.7 | 12.5 | 6.2 | 12.5 | ||||||||||||
| CIDP | 42.8 | 28.5 | 57.1 | 42.8 | 14.2 | 14.2 | 14.2 | 42.8 | 14.2 | 28.5 | 28.5 | 29.9 | ||||||||||||
| HC | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 0 | 7.1 | 0 | 7.1 | 7.1 | 7.1 | 5.8 | ||||||||||||
| ON | 7.7 | 15.4 | 0 | 0 | 0 | 0 | 7.7 | 15.4 | 0 | 7.7 | 7.7 | 5.6 | ||||||||||||
| HC+ON | 7.4 | 11.1 | 3.7 | 3.7 | 3.7 | 0 | 7.4 | 7.4 | 3.7 | 7.4 | 7.4 | 5.7 | ||||||||||||
| IL-5 | ||||||||||||||||||||||||
| Threshold | 11.2 | 4.4 | 31.9 | 7.6 | 5.9 | 16.3 | 6.3 | 9.8 | 6.3 | 13.3 | 12.8 | |||||||||||||
| GBS | 0 | 6.3 | 0 | 6.3 | 18.8 | 0 | 12.5 | 6.3 | 0 | 0 | 12.5 | 5.7 | ||||||||||||
| CIDP | 0 | 28.6 | 0 | 14.3 | 28.6 | 0 | 14.3 | 14.3 | 14.3 | 14.3 | 14.3 | 13.0 | ||||||||||||
| HC | 7.1 | 7.1 | 7.1 | 7.1 | 14.3 | 14.3 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 8.4 | ||||||||||||
| ON | 0 | 21.4 | 0 | 7.1 | 14.2 | 0 | 7.1 | 0 | 7.1 | 0 | 0 | 5.2 | ||||||||||||
| HC+ON | 3.6 | 14.3 | 3.6 | 7.1 | 14.3 | 7.1 | 7.1 | 3.6 | 7.1 | 3.6 | 3.6 | 6.8 | ||||||||||||